Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference
07 December 2022 - 12:00AM
Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the
“Company”), a biotechnology company focused on the discovery,
research and development of innovative treatments for Central
Nervous System (CNS) disorders, today announced that Lawrence
Steinman, Pasithea’s Chairman and a member of the National Academy
of Sciences , will present preclinical data for PAS-003 in a
discussion entitled “Targeting alpha5 Integrin in ALS.” The
presentation is included in the Novel Targets for Antibody
Therapeutics track on December 7th at the Antibody Engineering
& Therapeutics Conference held in San Diego.
Pasithea’s discovery candidate, PAS-003, has a
novel mechanism of action with the potential to improve clinical
outcomes in patients with ALS. The target, Alpha 5 Beta 1 integrin,
and its potential role in ALS is supported by post-mortem human
tissue studies and pre-clinical studies which show a reproducible
significant improvement in behavior and survival in the SOD1 mouse
model.
“We’re pleased to present our data at such a
prestigious annual conference that includes a keynote address by
this year’s Nobel Laureate for chemistry,” commented Dr.
Steinman.
About Pasithea Therapeutics
Corp.
Pasithea Therapeutics is a biotechnology company
primarily focused on the discovery, research and development of
innovative treatments for central nervous system (CNS) disorders.
With an experienced team of experts in the fields of neuroscience
and psychopharmacology, Pasithea is developing new molecular
entities for the treatment of neurological disorders, including
Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis,
Neurofibromatosis type 1 and Noonan syndrome.
ABOUT PAS-003
PAS-003 is monoclonal antibody targeting
alpha5/beta1 integrin for the treatment of Amyotrophic Lateral
Sclerosis (ALS) and other neurological diseases.
About Amyotrophic Lateral
Sclerosis
ALS is a progressive neurodegenerative disease
that affects nerve cells in the brain and spinal cord, causing loss
of muscle control. It most commonly affects people between the ages
of 40 and 70, with an average age of 55 at the time of diagnosis.
It affects as many as 30,000 patients in the United States, with
5,000 new cases diagnosed each year. The average life expectancy
after diagnosis is two to five years, but some patients may live
for years or even decades. While 5-10% of cases are hereditary
(familial ALS), the large majority of cases (90-95%) are not
hereditary (Sporadic ALS). The cause of ALS is not completely
understood and multiple complex factors may contribute to the death
of motor neurons. Currently there is no known cure or treatment
that halts or reverses the progression of ALS, and FDA only
approved 2 medications so far for the treatment of this disorder,
both shown to modestly slow the progression of ALS.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Company ContactDr. Tiago Reis
MarquesChief Executive OfficerE: tiago@pasithea.com
Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
From Jul 2023 to Jul 2024